Stryker (SYK) Expected to Announce Quarterly Earnings on Thursday

Stryker (NYSE:SYK) is expected to issue its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect the company to announce earnings of $3.14 per share and revenue of $6.0434 billion for the quarter. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS.Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, October 30, 2025 at 4:30 PM ET.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.07 by $0.06. The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.81 earnings per share. On average, analysts expect Stryker to post $13 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Stryker Trading Up 2.1%

SYK opened at $387.84 on Thursday. The stock has a market capitalization of $148.27 billion, a PE ratio of 51.37, a P/E/G ratio of 2.74 and a beta of 0.94. The firm’s fifty day moving average price is $379.74 and its 200 day moving average price is $379.16. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. Stryker has a 12-month low of $329.16 and a 12-month high of $406.19.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s dividend payout ratio is currently 44.50%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on SYK shares. Truist Financial cut their price target on shares of Stryker from $415.00 to $407.00 and set a “hold” rating on the stock in a report on Wednesday, October 15th. Evercore ISI cut their price target on shares of Stryker from $418.00 to $410.00 and set an “outperform” rating on the stock in a report on Tuesday, October 7th. BTIG Research upped their price target on shares of Stryker from $407.00 to $408.00 and gave the company a “buy” rating in a report on Monday, October 13th. Needham & Company LLC boosted their target price on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Finally, Barclays boosted their target price on shares of Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research note on Wednesday. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $432.24.

Insider Activity

In other news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Viju Menon sold 500 shares of the company’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Stryker

Several institutional investors have recently modified their holdings of the company. Kestra Investment Management LLC grew its position in shares of Stryker by 116.4% during the second quarter. Kestra Investment Management LLC now owns 712 shares of the medical technology company’s stock worth $282,000 after acquiring an additional 383 shares during the last quarter. Evergreen Capital Management LLC grew its position in Stryker by 12.5% in the 2nd quarter. Evergreen Capital Management LLC now owns 4,646 shares of the medical technology company’s stock valued at $1,842,000 after buying an additional 515 shares in the last quarter. MayTech Global Investments LLC grew its position in Stryker by 6.4% in the 2nd quarter. MayTech Global Investments LLC now owns 49,411 shares of the medical technology company’s stock valued at $19,509,000 after buying an additional 2,977 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its position in Stryker by 4.0% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 373,444 shares of the medical technology company’s stock valued at $147,903,000 after buying an additional 14,280 shares in the last quarter. Finally, Nikulski Financial Inc. bought a new position in Stryker in the 2nd quarter valued at about $802,000. Institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.